A total of 1656 people were in the OPERA 1 and OPERA 2 studies. A total of 827 of them got Ocrevus and 829 got interferon beta-1a. More than half (66%) of them were women. The average age was 37 ...

Following on from information provided to NICE by the company in April 2010, the appraisal of Interferon beta-1b, interferon beta-1a and glatiramer acetate for the treatment of single demyelinating ...

BUFFALO, N.Y. -- Specialists in neuroimaging at the University at Buffalo have proposed a mechanism by which interferon beta-1a may limit brain atrophy in multiple sclerosis (MS) patients. The ...

On-demand inhaled interferon-beta 1a for the prevention of severe asthma exacerbations: results of the INEXAS phase 2a study. Presented at: American Thoracic Society 2018 International Conference ...

Cite this: Long-Term Cost Effectiveness of Interferon-Beta-1a in the Treatment of Relapsing-Remitting Multiple Sclerosis - Medscape - Sep 01, 2003.

Treatment was stopped early for other reasons in 37 patients in the interferon beta-1a group (19 percent; 7 were lost to follow-up, 1 died in an automobile accident, 2 had disease activity, and 27 ...

The Food and Drug Administration (FDA) has approved updated labeling for Rebif® (interferon beta-1a; EMD Serono) to include the addition of new safety data on pregnancy and lactation. Rebif is ...

Interferon beta protein, Image Credit: StudioMolekuul / Shutterstock This news article was a review of a preliminary scientific report that had not undergone peer-review at the time of publication.

The antiviral drug remdesivir was used as an active control in the study. Researchers noted that interferon beta-1a played no role in speeding up the recovery process for hospitalized COVID-19 ...

The primary outcome, time to recovery, was the same — a median of 5 days — for participants receiving interferon beta-1a plus remdesivir as for those receiving remdesivir alone.

Alemtuzumab significantly reduced the rate of sustained accumulation of disability, as compared with interferon beta-1a (9.0% vs. 26.2%; hazard ratio, 0.29; 95% confidence interval [CI], 0.16 to 0 ...